0001144204-13-035486.txt : 20130618 0001144204-13-035486.hdr.sgml : 20130618 20130618163258 ACCESSION NUMBER: 0001144204-13-035486 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 4 CONFORMED PERIOD OF REPORT: 20130614 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20130618 DATE AS OF CHANGE: 20130618 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Apollo Medical Holdings, Inc. CENTRAL INDEX KEY: 0001083446 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MISC HEALTH & ALLIED SERVICES, NEC [8090] IRS NUMBER: 870042699 STATE OF INCORPORATION: DE FISCAL YEAR END: 0131 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-25809 FILM NUMBER: 13919770 BUSINESS ADDRESS: STREET 1: 450 NORTH BRAND BLVD., STREET 2: SUITE 600 CITY: GLENDALE STATE: CA ZIP: 91203 BUSINESS PHONE: 818-507-4617 MAIL ADDRESS: STREET 1: 700 N. BRAND BLVD., STREET 2: SUITE 450 CITY: GLENDALE STATE: CA ZIP: 91203 FORMER COMPANY: FORMER CONFORMED NAME: SICLONE INDUSTRIES INC DATE OF NAME CHANGE: 19990413 8-K 1 v347805_8k.htm 8-K

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): June 14, 2013

 

APOLLO MEDICAL HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   000-25809   20-8046599
(State or Other Jurisdiction   (Commission File   (I.R.S. Employer
of Incorporation)   Number)   Identification Number)

 

700 N. Brand Blvd., Suite 220, Glendale, CA 91203

(Address of principal executive offices) (zip code)

 

(818) 396-8050

(Registrant's telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 
 

 

Item 2.02 Results of Operations and Financial Condition.  

 

On June 14, 2013, Apollo Medical Holdings, Inc. issued a press release announcing its results of operations for the three months ended April 30, 2013. The press release is furnished herewith as Exhibit 99.1. 

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

99.1Press Release of Apollo Medical Holdings, Inc. dated June 14, 2013

 

2
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  APOLLO MEDICAL HOLDINGS, INC.
   
Dated:   June 18, 2013 By:  /s/ Warren Hosseinion
  Name: Warren Hosseinion
  Title: Chief Executive Officer

 

3

 

EX-99.1 2 v347805_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

 

 

 

Apollo Medical Holdings Reports Strong Fiscal 2014 First Quarter Results

 

Net Revenues Climb 50% to $2.45 Million Compared to $1.63 Million for

Same Three Month Reporting Period in Prior Fiscal Year

 

Glendale, CA – (PR Newswire) – June 14, 2013 – Apollo Medical Holdings, Inc. ("ApolloMed") (OTCQB: AMEH), an integrated physician-driven healthcare delivery company that puts ‘Patients First,’ today announced its fiscal 2014 first quarter results for the three months ended April 30, 2013.

 

Financial Highlights for Three Months Ended April 30, 2013 Compared to Three Months Ended April 30, 2012:

 

·Net revenues rose 50%, increasing to $2.45 million from $1.63 million. The increase was largely attributable to new hospital contracts, increased same-market area growth and expansion of services with existing medical group clients at new hospitals.
·Gross profit margin improved to 24% from 19%.
·Loss from operations increased to $711,972 compared to loss from operations of $53,153, due largely to an increase in costs relating to stock-based compensation totaling $519,092, coupled with increased spending associated with strategic growth initiatives relating to ApolloMed ACO and its new business unit, Maverick Medical Group.
·Non-GAAP* Adjusted EBITDA loss totaled $82,094 compared to EBITDA of $55,772.

 

As of April 30, 2013, ApolloMed had $1.58 million in cash and cash equivalents, $1.32 million in accounts receivable and total stockholders’ deficit of approximately $935,000. For the first three months of fiscal 2014, the Company’s operating activities provided $12,972 in net cash, which compared to $131,160 in net cash used in operations in the same three months ended April 30, 2012.

 

ApolloMed CEO Warren Hosseinion, M.D. stated, “Our strong revenue growth in the first fiscal quarter points to the success we continue to achieve in executing our growth strategies and tactical expansion initiatives – all of which are centered on establishing ApolloMed as a top-tier performing integrated healthcare company in the rapidly evolving healthcare industry.”

 

Continuing, he added, “With Accountable Care Organizations expected to play a significant role in reshaping how care is delivered in this country, ApolloMed ACO is hard at work developing innovative, coordinated care models that best leverage the noted hospitalist experience and expertise and the strength and depth of our newly launched Independent Physician Association, Maverick Medical Group. We believe fiscal 2014 will indeed prove to be a banner year for ApolloMed and based on our performance, thus far, we’re off to a very good start.”

 

For more details on ApolloMed’s fiscal 2014 first quarter results, please refer to the Company’s 10-Q filed with the U.S. Securities Exchange Commission and accessible at www.sec.gov.

  

FINANCIAL CHARTS TO FOLLOW

 

Page 1 of 5
 

 

  APOLLO MEDICAL HOLDINGS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(UNAUDITED)

 

   April 30,  2013   January 31,
2013
 
           
ASSETS          
CURRENT ASSETS          
Cash and cash equivalents  $1,575,500   $1,176,727 
Accounts receivable, net   1,320,087    1,582,505 
Due from affiliates   -    5,648 
Prepaid expenses   85,200    72,628 
Deferred financing costs, current   67,113    34,614 
Total current assets   3,047,900    2,872,122 
           
Deferred financing costs, non-current   211,375    218,640 
Property and equipment, net   64,689    68,142 
Goodwill   33,200    33,200 
Other assets   30,981    30,981 
TOTAL ASSETS  $3,388,145   $3,223,085 
           
LIABILITIES AND STOCKHOLDERS' DEFICIT          
           
CURRENT LIABILITIES:          
Accounts payable and accrued liabilities  $863,782   $950,651 
Notes payable   594,745    594,765 
Stock issuable   828,709    159,334 
Total current liabilities   2,287,236    1,704,750 
           
Convertible notes payable, net   2,035,828    1,909,714 
Total liabilities   4,323,064    3,614,464 
           
STOCKHOLDERS' DEFICIT          
Preferred stock, par value $0.001 ; 5,000,000  shares authorized; none issued   -    - 
Common Stock, par value $0.001; 100,000,000 shares authorized, 34,843,441 shares issued and outstanding as of April 30, 2013 and January 31, 2013, respectively   34,844    34,844 
Prepaid consulting   (554,050)   (616,014)
Additional paid-in-capital   11,489,102    11,248,566 
Accumulated deficit   (11,871,387)   (11,022,272)
Total   (901,491)   (354,876)
           
Non-controlling interest   (33,428)   (36,503)
           
Total stockholders' deficit   (934,919)   (391,379)
           
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT  $3,388,145   $3,223,085 

 

Page 2 of 5
 

 

APOLLO MEDICAL HOLDINGS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(UNAUDITED)

  

   Three months ended April 30, 
    2013    2012 
           
NET REVENUES  $2,446,566   $1,631,844 
COST OF SERVICES   1,860,493    1,328,659 
GROSS PROFIT   586,073    303,185 
           
Operating expenses:          
General and administrative   1,291,393    351,547 
Depreciation   6,652    4,791 
           
Total operating expenses   1,298,045    356,338 
           
LOSS FROM OPERATIONS   (711,972)   (53,153)
           
Other income (expense)          
Gain on change in fair value of derivative liabilities   -    123,838 
Interest expense   (127,493)   (224,036)
Other expense   (246)   (5)
           
Total other expenses   (127,739)   (100,203)
           
LOSS BEFORE INCOME TAXES   (839,711)   (153,356)
           
Provision for Income Tax   9,404    4,000 
           
NET LOSS  $(849,115)  $(157,356)
           
WEIGHTED AVERAGE SHARES OF COMMON STOCK OUTSTANDING - BASIC AND DILUTED   34,843,441    29,965,878 
           
BASIC AND DILUTED NET LOSS PER SHARE  $(0.02)  $(0.01)

 

Page 3 of 5
 

 

*APOLLO MEDICAL HOLDINGS, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS – ADJUSTED EBITDA RECONCILIATION

(UNAUDITED)

 

   Three months ended April 30, 
   2013   2012 
         
LOSS FROM OPERATIONS  $(711,972)  $(53,153)
Depreciation and amortization expense   6,652    4,791 
EBITDA   (705,320)   (48,362)
           
Stock-based compensation expense   623,226    104,134 
           
ADJUSTED EBITDA  $(82,094)  $55,772 

 

*Use of Non-GAAP Financial Measures

In addition to containing results that are determined in accordance with accounting principles generally accepted in the United States of America (GAAP), this press release also contains non-GAAP financial measures. Adjusted EBITDA, as used in this press release, represents Loss from Operations before depreciation, adjusted for issuance of shares for service, stock option expense, amortization of debt discount and impairment of intangibles and losses on discontinued operations. Adjusted EBITDA is a key indicator used by management to evaluate operating performance. While adjusted EBITDA is not intended to replace any presentation included in the consolidated financial statements under GAAP and should not be considered an alternative to operating performance or an alternative to cash flow as a measure of liquidity, the Company believes this measure is useful to investors in assessing the Company’s ongoing operating performance and working capital requirements. This calculation may differ in method of calculation from similarly titled measures used by other companies. A reconciliation of adjusted EBITDA to the nearest comparable GAAP financial measure is included in the financial schedules accompanying this press release. The Non-GAAP financial measures, as well as other information in this press release, should be read in conjunction with the Company's financial statements filed with the Securities and Exchange Commission.

 

About Apollo Medical Holdings, Inc. (ApolloMed)

Headquartered in Glendale, California and dedicated to putting the ‘Patient First,’ ApolloMed is a leading provider of physician-driven integrated healthcare management services, fueled by its commitment to provide exceptional multi-disciplinary care in the communities it serves in Southern and Central California.  ApolloMed is addressing the healthcare needs of the nation’s largest population center by leveraging its integrated healthcare delivery platform comprised of three affiliated and complementary physician groups:  ApolloMed Hospitalists, ApolloMed ACO (Accountable Care Organization) and Maverick Medical Group (Independent Physician Association).  This platform combines hospitalist medicine, critical care medicine, case management and transition management that enable healthcare organizations to engage in performance payments for utilization efficiency, quality of care objectives and shared accountability arrangements.  ApolloMed strives to improve medical outcomes with high quality, cost efficient care.  For more information, please visit www.apollomed.net.

 

Page 4 of 5
 

 

Forward Looking Statements

This press release may contain forward-looking statements, including information about management's view of Apollo Medical Holdings, Inc. (“the Company”) future expectations, plans and prospects. In particular, when used in the preceding discussion, the words "believes," "expects," "intends," "plans," "anticipates," or "may," and similar conditional expressions are intended to identify forward-looking statements. Any statements made in this press release other than those of historical fact, about an action, event or development, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors, which may cause the results of the Company, its subsidiaries and concepts to be materially different than those expressed or implied in such statements. Unknown or unpredictable factors also could have material adverse effects on the Company’s future results. The forward-looking statements included in this press release are made only as of the date hereof.  The Company cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. Finally, the Company undertakes no obligation to update these statements after the date of this release, except as required by law, and also takes no obligation to update or correct information prepared by third parties that are not paid for by Apollo Medical Holdings, Inc.

 

For More Information, PLEASE CONTACT:

Hanover|Elite

Kathy Addison, Chief Operating Officer

407-585-1080 or via email at AMEH@hanoverelite.com

 

 

Page 5 of 5

 

GRAPHIC 3 tlogo1.jpg GRAPHIC begin 644 tlogo1.jpg M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$! M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$" M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,# M`P,#`P,#`P,#_\``$0@`3`%&`P$1``(1`0,1`?_$`+H```$"!P$!```````` M```````("0$"`P4&!PH$"P$!``$%`0$```````````````<"!`4&"`,!$``! M`P,#`P(#!00'!P4!```!`@,$$04&`!('(1,(,0E!(A1183(C"H&10A7P<3,D M%A=WP5)BLR6U.*&QPA@Y0Q$``0,#`08#!08#!@0'`````0`"`Q$$!2$Q05$2 M!@=A<1.!L2(R%)&AP=%"4F(C"/!RLC,T%8*2)!;QHM)SDS4V_]H`#`,!``(1 M`Q$`/P#OUU8D$NH%5N4BC2OVZ]1;..IVKQ?,&@T6!9?G&-8C'=?NTEHR%-+" M8J5I[[@VG\O:"2DK!H.E=7EKC))Y6\FIKQ"QUS>Q11.<_AP*U"GG%%R>;8M$ M!<6&0$EQTJJ$D?-U(2!K;H.GN9H=AZT^\==:O! M<-BD=S["?P7I3;6JJ@=-6Q!DU5R M!RBBG'H-7;`0P`\%\4=5HC1$:(C1$:(C1$:(C1$:(C1$:(C1$:(C1$:(C1$: M(C1$:(C1$:(C1$:(C1$:(C1$:(C1$:^'0514*`]03Z_T^&K87;B::??^:H-N MVM=:J8`ZIYS(J@SE4>O7^GQT$9H2OO,=BD6HI)-4A`!W5!KZ>M:TIKTA;S2E M>W,*6A#JPCNNT.Q"05)4L[J5`ZZV'%X]^0 MO&6K=KMNH&@V[?!:W?WOH1%XV^U-%W#EN[Y]D$S))LEL,35.KM\0%P,HCIW! M+FQ3A7N2`36M.GV:F3'],MAY9:'E;XM\N"T>\RAF!A'S'S6S,;R1^.EAY3SD MA"R"6T;=M/NHFNO>_MXV,^%463IHW:TIYI26'93)HTXQ:VE-K%63_.K<)"?F M(67K85_7-?,"14#7XK=;+*"$?%3["E*XYD[#B&V9? MUJYKB=O;B6BXKCL@JJ"](2TXVE(]"HJ"=:3F>GI(^5S:4)_>SW;5L\&7@E91 MW&ORG919ZU-8*%?FI=6@A*FXY[ZT%2@!O0UO4D5/4GTUA(;$L-#PWD+W-S"_ M6,U'D5<5*H.GJ/7X^GPZ'UU<,C:--RJ+2=BBTI2D`JH#4B@K\.GQ)U]-*Z;% M30C0JIKXB-$1HB-$1HB-$1HB-$1HB-$1HBPC-N2>/^.8<>9GN=X;@\>:M34& M3F&1V?'HTIU%"M##EVG0DOE&X;@@G;45T167%.9N*L\N2K)@O*'&^;7J,VW) MG6[%,TQR_P`MB&HJ2N3]):KK,D);0H`$D4%17U&B+P9%SUPUAMQ39'\@6J5D."9 M/CF96""_+@2KEB]W@7^"+C#8CR'8[%TM4J7`D`-2D=4*/4^NB+-HSCZS(#X: M31XF.ENH68I;;*%NA2E?F%PJ%10=-$7KT1&B(T1&B(T1&B(T1&B(T1&B(T1& MB*!-`2?0`D_LTI71?"0T%QV!:UN?*W'MHN,NT77.L0LUTMSJ$SH%WOUL@3&D MN--OHK&E3F'FU+9=2H;AU!!]->YQ98T2.!H\::M6(9G+5SS'4\P.OPN686&_ MVC);;'O%CN,.ZVN67OI)]OD,RXDA+#SD=U34F.MQET)>:4D[2:$4]=>HI6G4:G#METW=9,ON[1G.[FY#4M%*`'2NN_51?U5E( MK)WIW+N70TI4Z>Q(0QJ\JD/09+2@T&$(@QXF\(0MMRK>Y2E$)3N#AZDBFIQR M.(GQ^-D;,P-DY?X3[EJ&,G9<7C+DG_I6G4Z[/+:?L2P^"\,RCE.:XJSH?9L] MKE_37"4L!I#)2I`6&P_M5(`*QU;"AJ$&=ML) MEV7,P+3;SJ2ZQCQ]20P5XN/N*5#Q![K&6Q;PS;.8S':'+VML^6QC> M^0;`Y\5#KKO&Y9+&=QL09FMNIN4;Z-D/X%/.\:'@@BNB*;O-4*BM*4A81N6=B2H@$!*E4"@=W0BH)T106^AM.]0<*= MJU50TZOHA.X@!""2I7HD>JCT%3HBE3*CK66TN)4XFF]I-5.M$MAT!YL`K:46 MR"`H`FNB*IW6RA2TJWI2"3L!6H4K4;4@JW=/2E:Z(J0EQRG=W`D;0H[TJ01N MIM0I*PDI<57HD_,?LT12KFL(`/YK@4G<.S'??/1004D,MK*5I4:%)ZC]FB+U M)4%)"@"`H`@*24J%17JE0"DG[B*Z(J2I#:5.)5O':2E2B6G-E%4IM7LV+/7T M!)&B+EO_`%0-P?@\(\`!F9<(2)&=W6/*=MTE,=T,.PF5`+__`*%*EM=*?9HB M;C_3+S;O(\P>483UWO3.J$^8S,5%<;N]@1$>8+R'$=P=Y5/4#XBFB) M/GZ@R5*A^Y+F5G:NMZ5":XLXUE,E4Q,2)]6Y(RG^;A,:V)B+2EM*&O4?/\*] M=$705^FC4].]O#.')DN0Y)/DER9"3)E2)+Z&(+.(\ M1N=&<2V=ZFBZXXRTW);XELO% M/;IU5R.^U?&'U#RMVU4%S([827'-F\[4!25`K5M*]J4D5 M4H)!-!UZ:J$3R:`:^87C=7,-G_J#3V$^ZJE^OC;5*"UK*0%*;0TZXZ$J4$A7 M90A3NVI]:4T,3P[E-*^87RVNH;L5@)(\01[P%6[[5-V_Y>OS4504-"":4!!^ M'KJ@-+A4;%ZRO;!_FZ?V\%3^L8VNKJY1H`KHRZ54/H4)"-S@/_#77U[#&T.= M2A\0?338?R5[]+/2M-!XA01[2DJKM4V]L[3J33U23K+-A M>Z,2MH6.V:CW5JL7-?VT$ABE)#QX'WTHJXE,&@[@"BG=L(( M1W-RZ5\PO0W4(9ZA)Y?(_DI1,CJ!(4H`$"I;<2"3Z`$I%2?NU;7]Q#C8/J+P M\L50*[=O@*E>UN]MU&)8-6'V>^BE5/C)6VCTNFZI0H#Y5>J@0GX=`3 MJJ*1CI_1!^,:GR\]BMY0Z2UD='MY'4W;CQ7(?Y]2GU>8/.ZYJ4TZ]?CKKGI7IB#)=%V5U'&UTAB?4D,W/?O( MKL"Y+O.H+BQST\,[BUHE.]YW^!*?U]L=Z4[X9<2*EN*/XI?%%[R MK^&O3K\*T]*ZTOF'-Z@_RU(',RG)^M>20\A@K==.UM+L8$GT'YBJG]@U=%I+ MA3>%BH#_`#'^:8*]S5^X,\[X)="XHVNX\<6^-'0/PAZ+D.1NNF@'KVW4FNNH M>R;OIX)F;Q/KY\K5!?<>IG!\#^*21QO'NFNF7B+CR#QEA%EL,:$PU M+9B)%TD(2@+?ET)<<<4"2LE0`UQ;G6HJ$,1WX#31*W$,H*6^Z92$$T37UU. MO;GK8VL_^WWQ%7-^%Q+JN(W&G\._?3BHCZDZ3-U65@J`=GP_BF9%8HXGL-HC M)^LC%;!50=5(JWU/QH1KHFVOFY"VI7:/'\5#F0P;K.YU%*'^'AX)0WCQRSDO MCQG%LR:WBY_X24^FWYCCKKBRF[R'B$?5VYEQ2@$)>25?)M%#J(^M>DAD.9P; M21VP@,KX:E2#TCDW68:-P\_P727B&0P["O,)B?&!+>]AJ2VEU, M9T-]$NQPK:H'J".NN9[NVDL[A]K,.66-Q!&FA&W9I]BG6SF^HMVS;G!>R_J' M\IF(,ER$7&74B6VA2E1]C:WU.DI2H(2EMI74]-6ZN5PB^Y+[Z'D3RKS%E?&W MB_FO^77">,9+;4\SE,:;%0E7=2:*10 MC[M$70'[(GO`\V^1'+`\6/*'(6LXR+(K%=+UQYFD^!8;1<)ALD+?*Q\L6"#: MXCRF0A"@ZXT707NJZ`4(LD_4$^:OD]XKY_P"GQ^Y/N''<+)\=NKU^3'BVN68 M:XDJ>D7%UBYP)\9P-MM@G>D]$=-$3(N(^\W[B-WXJRKA/#\ZY'Y&Y9S+.7GQ MF>,XCBDO+;A9%8[9EN0<7MS&.A+SR4,.!';CE6X]#HB31CWN)^X5X_\`(,BY M2^9.88.88V_'NJ\"Y(AK87>.XI$J5&DP9ML2R'?S%A:*`(4"``!31%WL>VIY MJVSSF\8,5Y0=;BHS^$^WCG(UL1\C5KS=FV&YM-+;:VAM#MM++A2/3?T%-$7/ M1[NWOC\KX_RIE_C+XBW:!C-KP&ZNV'/.4([C!5>ZNSQ_`\@$9QY/-XI,F+DSLLDR9+>'-Q^XYO>:>+2 M8PBI4FFX#:/31$]%[//O93_P#1[(/^]XYHB3I^H6__`$QS'_2O#/\`G9!HBZ"O MTS3E/;IS)3JD!M/E1RBE\R2$H$%O#N+B\1NH"VA"B:_?HB:P]U#WV>=)O+V9 M\+>*>96[`^+,%O-SQ/(LTLEN9O-\RR[!B*AZU6XHM]V<@R;2IQ*SVPSN[X!* MJ=")J6^Z-Q_@D7GK(.0_*.'Q_>G6W+9E5[7.M5F2I]Q*69;,:1'B]Z,AU M8(3VU;P*`'TT1=`OLM^\YRASCRG'\6/*2[6RYWNXV9R7QGR3,3`B29[K,!YP MV^6$-1@[*6Y'6D$ME14H`FG31!J4X5[G/D#S?P[G.#(XMS>\8PS%Q3$9 MQQ<20\BXW)KO*_G$1]T.++*2-M$TI371':KHBUZFQLCIZU;,!HUA_2T_J!XK MGKJOKBZPN;DB93DUVF0;Z;&E(*Q7W`/+.Y8I>,'MV09#D>>W2>VTS-79['<9 MD2UN6XKVI&PJ/XJ:W3J#M=A,;=1W(FEA:TM,50YL<6^E""6^*PL'7 M^1Q$XCE.\#5\F[R*6)R1[D_/O*''&$XCQS8\D9RUB!#_`,P,EPFVL7^[7QUF M&EF9+B8W#CW&XVEB;,5W5J7$8#9(`VCIJ*[?MUB,!?\`/6MO4B:W4$Z.?Y[RDA6#RR\G\$S>%>)W(N:*79W)]P.(WE?>?>8 M;D-)4S.9+"NT^TERBF5E*FC5)2D]-2;/VTQF2Q)N(FCE+*@M9$/:*A:+;]RL MACLH('T^8#5TI]QHNG7QU\@H',_CQBG,4Y$$-W6P?6W]*]J"Q(CQF7)32PC: MELI6L^M!KD[-](PXW/G%1`OF!;R5#*DFM*Z471UEUK-<81M^X,#"TUU?NI[= MZ8U\IO<9Y4SG.;QC7#M^;N2+XF.;$6M--0*`J",UUW?W>2]*,`1M?I1TFH\=4G& M[;7'T%&5W?-.4;#(N+J/H;YET=R-:5_QI9*7H89;"MPZ%(J-,?TCA+R^< MV!\;R*5#1$ZFN^@-/:KR^ZLR4-F"^H!&AYI-?O3T_MZ>:MZYVBRN-N4)$=S/ MK1&1)@38@;[5YBVYIQ^;)/92E-4`)KT'0ZASN]VX=B32U,CK624$D^F*4((` M`IH?)2]VVZNAN^G(?J2!<`._>=@&\U]ZQ+W(_,[+>$'K!Q?Q!?&K+F64,/WR M]Y`J(+BFT6A17#C1OIUQIG:7<7H+K:5AOY%=:BE=;SV0[.VW5%DZ\RYW2;X[9W5R\@N,1W_$EL0*]U118DMW`MI"?1/TP^RFI7M^W'1KKVYM+ MV?T721.:"8X@:_$`&DLV\%"O3G>4N7WF3^IE`$CR":<=%U">V82KPRXB=4 MG8M^/E,A:?2BGLSO[GI]X5KC#N8:]377FW_"U=5]MA3#L/&J7S_#^S_Y:CT? MZ<^?XJ1C_G>Q8'E5P<9:=:/1I*ZDCH20`02:UUE.3EY'[B%80FKWCQ35?N'< M=KY+XKM>5X['7.O7%]Q=N3UNAC_JEUM]S[#'TK+C>U]R-"5'6X6]VT;R:=3J M>^V=]]%DQ%)4-N6_!K1O,P5=77:0132I4&]PF.>2]NQM:^W0)&/MIP4Y3Y#X MP])C_6P[9%O;HF2,<'`4IP"8FYSXEC8ARKG=MC,);BSE,38*6VTMMQTO*B2` M&4(`2U5+G7:!7KKI_HSJ0SVS"XBI:-[MJA'JJQ:)CR@?,=P6I',1?=VEUD.[ M3N1W`%[%?:C=7:1]HUN.3RMNYOQQ.U>$5XD/\7W+%)C MLA7(2\\ZXXL,71]Z0AH.+4I00V&Z)`-`#TUREU>]C^H;A[*2^6/-5VTVK#\L@9T];LNMO'MI;$3&I/UJH$6 M$U`:D28KZ9!#C90H*H*@]-$61>\7[M/AAGWBSGOCAQ'E\SE?.+@Y!MR)F-X\ MQ(M^#(C1EQ6Y;KEYA1FI:6P=P,?OJ(00>E-$3#7LIT:]R'QHV2/J7H]YD,BY M)"F7Y0E/P1)<6SM;^B5):(;<:0E"%)0*@UT1.X?JC"PGDWQJ,A!6RK&KFEY` M']J@W*XU;<`_&VL"BDFH(Z'1%8/TP'&.,Y%R]SWRK<[)!N;^*8)8+'C[UT@1 MY[MCO`R25->GV9R4V\NV7!5OE):+K!0X6P$UVBFB*S_J>>)\>Q;G/@?EJR08 MELDY=@4O&9Z;?%8A&7=6;_?;BNXR?ID-%Z+YUB\);<%9B&%<&[K'C3S'^G+?8<= M<2L+4BA54UK71%U^_J9IRKKXS>,-U4`G^8Y0B5L`VA*WK0V\NB>@']J/W:(D M(_ID/_-'D_\`T>R#_O>.:(DZ?J%O_P!,QUY? M9XV\['=PS-_)K($265K9?8-GXHX^F]QEYM2'&EH[8(*2""*Z(N3CQ^L%IY-\ MD^*(UXW,0.2N>K#`N*&JI2M>69):K8Y<)#:"$NR5-K%7%`J(0*GH-$7T>_.? MB'%,S]OWG_C1%HA*9QSQYS5S&(ZX$9<2#><-X^FWRSR832VRW$>5+9;JZ@)6 M5?'IHB^W/M)FV_GOB)J8X@I;7'@L9=B\:YQ67`$K;C2VT M.I=;20EP+4%`A1J0+M`]X9XR\XX9GL)0J%-Q<2EI`26Z/7"[.`;:44`%"E== M5=@)+@MEMV`T]8;_`.%JYA[K6]O'?FY<0"0=PXFNY7;V<,,L%PRKE[)Y<6'/ MG1(L5F!(F1(\N1;27K?4P7I#;CL,E-4_EE)VDCTUC_Z@LS=6,S(2YS&<[JT< M[70BA`-"%G.UN!LLE`Z5]'#D&UK3P_<%I+W9X,"W^35L5'B1FNYA,27(4U&9 M95(>WVQ?>>+;:2ZZ4DCDI6:N#8R1\1.A>"!J=@K0+0.\& M+LL5EV\E!5W[0/T_PA+"]G#$<>=PSEO,#;X*KS.RFR1VKBJ%&5<(\1V!=5.Q M&YBFC)1'>*$E384$**145`U!G>#+7<&?^B<2V$N((YC0FH(J`:;M%+?:W!V5 M[T\V[-"XQC]+=/M%4V_[CUNAV;R[S^-:V&(+*K=C\DHALM1$%Z?$DO37"B.E MM/M#"P@#U@*4 M`X\!1+U\:;ZO&/:5Y.O<99:F0G^568)0KMJ2XBZ1&HS+:TT*&VDDA*10)3T& MN;[N&YO>Y[80WF?ZK-*C8.;B:+H8OL[+H*"=QH'M<`:;_AX"N[[TSGP;=L4L MW-O%>9\@MLC%++GEHN.;-N,I>;$9UU;BFG62DAY@]I54$$&GIJ=\Y!F(.GYF M637?5F-P9\0^:FF^BB#'NQMSE&^HX%G,*_#X^(3U'E;YI>)_./!N4X%C^8IN M%W?BK_ESHO7N8G,A+"#\ M;=23I4!QKO4@=4?[6<2V-CZ\G\/AY)MSVWKO*Q[RGP);24RU2HETQHRFY,R& MD1IB0TVM<.2N,MQQ?U)JKMG>`!4TH)H[JV]G_P!F--P&_5U)U:"=C:?%0[_% M1IT[/?QW#!9\QMN<`4<6C;KH"/B6S;\3H9"2#RDGE(U(I4^*RN>AAN MEYG<;I=Y$Y=OA*ER8:KF_; M0W(DJ9[\AM!@J`0M2DC7%O4W4O4,_4\MK(7B)KB0?5>:?$=0.;0CP70W;SI? MI^+"&9L<3W.8ZI,+*[#OY=4PMYF8A`P;RAY3)RVT[VL8UPYMY*3 M--R?^5W-N:F+'E'LW%;L.1^9$DL-1@M]J0E25C8M%0.A(KK>K*29EC]'&P!X M<"V0?.VG[3NKOH5HN;Q4>8EYYGN8#6H`!!\ZK2?C;P;!X\\F[5R#QC=VT\69 MQ!R.\Y1C\H1HYMN6R+?=XZ&+84$K=87*;8/SJ2:DT&KKJ[)WN1PD@N6!M.05 M!K74"IKO.WS5?3F(M\1>,+)'/`)V@#=X)X%#JW$E7:6C[B4^@'_"HZA")4K1ELXJ7$'P5%$@[]NQPI!^90!`3]GXMM=(I+R0CU86M:?$*MT<$+ M:ND=7VK6?*',>$<665=YR:\06&T2&H[4;ZELRG7UK2`VED*[@)!^(`^&LSC\ M)-D)J0AWPZFE/Q(WK$7>9%L.6(-?734E(PYK3;2TC*P_7S%[OAJ M`=-=H\5IAC!I"GG&WVRV$)^4I2/F(]:A736R3WDD[:.)'M*MK2T9:&K?B\P$ ML_Q4L3UJMN6)4V6D39$6CWHJL8/H`2*4.X+Z_9J$>H01EY023KO4FXQW/9,= M0"HV+8_DURI&X4X!Y4YAEHB;..\$O>6H^N:0[%:D6YALL.N)<0M/Y;CGK3H" M=857Z^:+EG(OD=[C?D_8X&=9/+,]%EK<(47(VX!L4^.B)^7RH]B+Q\\*_!+F#G'(,ORWDCF[%\7BW]B3#(Q" MR6W('81'A M)0^7C'8B02^E;B$5<50]-$5B_5#Y%;I65^->-H=C_P`W_D]RS.W0)*EI4Y;G M)E[L%Q+J6PH(;C,QG9#137>Z`#T.B+4GL!8PN]\7>X5DMN,R07^`>1<1M3:V MU(:NJY6%1I/:EA'X7!+)#82#5"0?71%SC\9Q)-CY:XGM$QQR.Q;^3^+(+L28S]/*@Y>_ M;I#/P0]`MC499%>M5%'7[]$2&_TR'_FCR?\`Z/9!_P![QS1$G3]0M_\`ICF/ M^E>&?\[(-$3GOM78Y=LF_3[>?N-V9I3]UO\`/\L;9:6D5*GIUUX9P6*PT`FI MW!Y*0*?[VB+F*\3HZD>4_C;)8>1_*V^8N,&4I#K"%EY.<1(:)2`\IM&]B:RO M>:_*E-3HB^F5Y1WB#:O$+R*N4P*9C6OQ^Y-D3Y"U1D[41^,[C(*DDNT4F0T- M@I4J5T'PT1?,6\>>W>O(/@Q5O1(9^I8=-@_4L[]E_\F3S4E*=U&XJ^I^U^ MWBE/3XZUO^IZ9\UXP-B8/C?L]JVK^GR62XQKS*XUY6[R>"3[[NRPCR9LI*0K M=@$$J!/3J+55/3X=::E7^E4M_P"U)VR,:1Z6TC^(*,/ZDII8,_!%"20]]#J1 M3X"EL>S90\55'**'\QF[PE5(/\`PUUS M#<9!V/[PMGCB9(XRM`:=AKS+HB^Q#K[MA:ALTK3&"XD;?TCBFJ/'O!;-RISK MQ=@&0*_Z#R/D]@LU^"-A;C,,J>2Y.9*R`N0?J#T51.NB.MLY>XGI9^6990N+ M(W.()H*`#AJH&Z,LWY#J=F,FGDC8Y[1S5J=2=U:)]?+/;`\4<2L\_*LKR._8 M[8K(PZ[=[JN\SHZ(ZFVRX$%,2:H_A0HD4K]FN5>FN\_6,^:^DM\#95=3E/J. M).O`FGVKJ#J+M9AFXATUQE;MD;14'E:013?O\EC?CEX_>$UDY4Q[(N(^3G,F MS=@L76T6F?]6=49MIL<]9M MM'M%2(W::_+\(/+0[#1:!TSB\;CL6QME)]2QKJA[V@$ZZZ[=*`^U-)^<+;7?K]RY]?/VXHG>87-$^(ZF2W'NEN^G4#5*WHV M(V6&\C8NJ)H#O>SO)'EIZ?!*UD#[AKDGN=5G4UWQJS_``M7 M2O;H!N(C#=FJ<`K_``TZ4]?VZCQKJV9=OK^(4@%Q^H`W42:.;K;]($W%`4EM MU72@.K8=;*%?E M)/`6A, M*!'><;+DIQ76:V&U!L=IYS?U(/RZVK_8(;R$P/:"UVXM:?+:L))?")WJ5V>) M5]3YC\S8@SV8N0-W,HK1=V(?]?@2MB2?AK%W?;&*\;RL;Z>NUL;/S"H/5KK; M8[_SN_):YSGS\\DIT,1K9>L<]+<=L-MLL"4A]#RT*ECYI5T;9C[4-%S\WJ-M=6G76-L>G(H7V#&,E>#\K M&L)T-/E&NM-JO^B[ZZS$D_U#G$,IM<7<..Q/CWG$_K[TF>Q##,*/`GX^Q#0E M(1]%$N+/^'YJ0"!MC6>"AE-?F`73[=1S:Y!T4(:]WQ'4[OB=J[9XU6_.M"7: M5HK6,-7+D,,(W*D+4`XTE/S#[:DD`]3]NKG_`'6FUVGF53]&?[42K,%QEK%[ M*U#2V`ZZMQUX@"NY1J`HUZ^IU'V4G;\7Y+CK`9"E.[Y<<+0EM*2DE14T.@-3K'J]7S%N-\WS/Q<\C\, MSU,*=9\^X`Y"@9Y<;30G&>'(SC%+G:8_'F?VK(I]WA8_=(:GUO06I2H-NN[ M3(>DW%L(4I"=JJ&HIHBQ[SW\\.1//_F&UENH2LM[EI755*G1%V%^P)X@YCPUX69+E?)EG-@R+R3RA M[(DV!V.VW.Q["K=`9Q.+$F-IVMH:R2WV3ZU*4DJVRT[P%;@"+D*]R#Q-Y&\+ M_*KE.QW''+K;<7R/F/),RXMR2XQ9!LERA9'=+AET61'EP$SU0FL>$XQQW4MD M+9`0"*:(G/[S^H1SZX>$%L\=6>+&V.1','8X>G\C*O=4.6VU6Y-K3/&"3BMV_P`F<&R!.2YCEK$!UFPV MF]8I(0Q;K47)HA2)*GRZX6U-H4@ANI/IHBZ$/U1JT?Y$^/C:/F+G(EQ4GMI4 MM)6Y"WJ^9"2G^$]3HB;R_3'.(5YG\FK"@4KX?R,)5U`46[WC>\"OJ4UT1)Q_ M4+2&3[F65T7TD<:8K$85L<"'),-V]_5,API"`MCOHK4@?-TKHB?W_3<66V9; M[97)>+W!7U%MR3R3Y?LTW>W^4&+A@_&$9UH!S9WT%"^A35!/2NB+D&\M/&GD MWP=\D^*LAOZ9<>W/VN?-9MF^(V_!\VSI%V#D1V#;&D1[J^VS M'CE2QDUL28R$E(^=?S%(-=$2?/9#\'LK\G?+3`\_FV"](X;X9NEMSZ5ECULD MP[*UFN-RQ<;3:$JG)ANR)#LZWQ2%LH<;'=!KT-"+HS]Y]Q/^8/#[Q([9L,A@ M%/ST=3<[TZ6RE-5)(1UZ@"FNHNP5]!81S.F<&N]<;:_M;P7-_>+'S9(AC&DC ME/`[SQ65>RVXV]*YC<0K>V\S'"%$%._MRX+:R`L!7RN((]-6'?ZZMK^:"6,M M/\TU^QW$++]DK23&VSXG@MJT%18C:P0H*D-HM[BF MA0DA:6V5']FMU["YRUPO3$TX.IM'Z]-@X+3>]N!FS&1P!"YV[@X">_ZM^JY2?Y MP.P'CO)3J7MV82QR1[>5WP222VQE61 M/']Q6YES>>*.1CZ<0*U4_8NRDN.BF8\CXN1PI[&[MFXIB')L4SWQGY97:)=L MN=DOV%7ERXXK/E-E*9[D60"P(\ALO-HWI0*;E#UUU<_J_IW/=/\`T4IMWQN8 M10@N!!`W.;0KGQF$O,-G3>,:\$.'!NP\0:I:/D][C=^Y^X@@<91\/B8>J_\` M;F9;=8$^BB#@:$:2/J=/L6UO:;\=;[>.2;KS_?;:^U8<2LE MRQJP3;I;TP#,G9'"?CWV#%BA)WIM<1N*XI:@`KZ@!)-#32.^F3M#UYQ1_W0Z>NX+HW4;7$.(-0`/96JT1XT>>W)_C'QRS@%BAP,BL]QFW M]5B7)4*6=UVV)OOS*\.JY]=37:ZO%=1?M>%7_`-*>(2L*!`S,@*J#VW<\R1V.JAZT M)_%;^1_.'&BL%_LT.]P)EIG,AUF:TXE+I2E79*TE(VD]04GKK*V=ZZ&< M.C-"-H!VA6UW&UT9J!5-=F MI>P]RV2=C#351_>S.%0":+16379:2J*PYWWZ[4U))/[];\)8HVDT"U:[+W'E M!*A@'#?*O+N06^R8ECDIBXRU*:C94^/^DPH*E*^L^H("CW`G>!1)^&M`ZEZL MCQC26N#2`?U$?@KW%8)]_(*U/L!]Y3_WC7XGXQP#A#=H@I;G93G37Q5)`?-WMG>%'D%EJLOY6\?<6R#);@FERNT2 M%#C-OJJ2I''"&*9#Q_@_"''5CLO(%BNV&9$A M%C@+G9A:;U%5#N]JO4MNWE;D:9%?V.)<*@M*NHIHBQ'!_;6\%,`R3&,OQ+QN MXNQC-,7O]NO%HN<7'[:J=;9UKF-36A#G(MB7.TVL!:$_(-RC^TBYS_U1%M;; MY'\7EPXY[:+#=HLN(AT-V\PX4N9-#):J`IW:^>W\OJ1U&B+U_IR.)N,^?N&O M+'".4,1L7(N%7+)K7&_PY?[7$DR;>#"L'<$50=FD8[ MS+QCB6=6M]I+17>K=$G/I;:6EY`;>DQ5N,C>V/PG1$A^/[-GMMLS&[BUXTX5 M]49)4`J%%+.\E1/RF%M**_"FB)?G%W#O%W"..1\.XHP?%L#LC+`93:+!:XEN MCRVXB0PT[*7$CM!;I1^(J!))T18ES;XU\%>2%JLN*\SW>K9:;Y M;X\V+!D*8=:6J.9$9U(9>[HW``5VC[-$6"<(^#WBUXX9#)S'ASAG"^-LCN-M MGV.5.Q2!$A2)$6XN17G6/J(T*(O!?(JUP;3S MEQ/Q[RBY$CRF8]PRW'[;<+G:F)?11M4J3`F/1BX$@*VJ2#M&B)&;?LS>W+#5 MWH7C;CQ7#=$YMI"(\>!,D,*#Z(;K26`VXP\M(0I!;VE)H?CHB<1X_P",<"XO MQNV8+Q]C=BPS$K=';+&-6&W1K?&:="RYW-T5MI"U!0`/3KMT18CR+P+Q#RO< M(5PY$PG',FN=NWMP)-RML62^EH=T)!+S*S5*5D>IZ:SF'ZKOL'5EA/Z=75(\ M?_!:QF.GK?)_%.SF-.`7IXZX1XKX?;G_`.7&)X]A[UT5LG.6ZU1F%2T]P/J8 M<4RT@ELN("OB`1KQSO5M[F`'7\WJ%IJ*UVKUP."@Q>ENP-!'`*V\A^.?!?*U MVA9!GN`XOD5XA-EMJ;.M45][YD[2-SL=14:^E2*:\<3UW?XR,VMI<>G&=U3^ M2NLITK:Y23U;B,.<#75H.[Q61<8\32KJPP\%E`886AK>7@%A^;^+W!/(V M7.YEE_'&*Y+E$E<)4F[W2TPI4Q:++'?@PT%Q]AQ:T1&9:D!)-`#K8<9UAEQ[ZNY3 MV+;;HJ&&$R+@ZTXI;2&VFT#=M^;H*FFL9?WL^2N#=.+G24%37@LWC\2V"`6S M0.45W!8CR;P#Q%RVDQ\]P.QY`:[DW!=OB*FCI0A4M38>2.GP)U=6/4&9L6>G M#+(R,;!S&GL"LHZ-ID/!C0?M6G[=X'^+EHE,7%OB^R1I,5276E"- M'=;#B#N`(+8W#I]FLM)U[G[5ADBN'AHW@D>Y:_!VRQM[\-S$?:UI'WI5EALE MDL%F%ML\*!:;.VA13#ML=$5C:I`05A+*$!"REL`D`D@:TK)YV\R\1RUY*^2X MHKB,QW-S04V[#L6GX7MA8VKO5].C:G]#>/FLORWQ0\?.0KI M`R/*N*<%OMTM<%RT-O.6*WK3'@%+S2&$LN1`E8;COT'IM'IZ#6-Q/<#."W+( M+R1P)WN+O94Z@>"R&9Z#QPD;((133]#1OVZ$K=6!8;BO'6+P,.PRV0K-C]H4 M\F#:[?';B1H29,AR6MIMII"$44X^5=!\=:WFLE<9&Z=<7)K.XBOW!;9@\9'C MK-L3``-=P'N6A`(/KJ@``U&A59`<* M'4+RRH424RXU)BM265H4EQAQM+C;J5"A0M"@4K!'P.O:.>:%XDB'I-M@1;?)="P0I0>8;"@\:]% M>H.LK'U)U!$X.BO;II&RDCA^*LG8'".^:TMS_P`#?R6&V7PH\L>K#MR5[_\`*_\`->9Z;Z>)J;&UK_[;?R2B M\;PW$<3MHM6*XY9;#:MRUB!:+?&@Q"M1(6OLQVT-E2C6II4ZQ-WD\CD'B6^G MEFD`I5[BXT]JNH,3C+84M[>%@_A:![@LD2VVC:$(2D)2$)VI`VH%*)%/1(IZ M:L*`FI&JOP`!0:!3Z4'!?5`I!ZD`G[P-.4<$4=?41HBI%AE2'&U--E#U>ZDI M&US<*'>*?-4?;HBD:B16!(#,=EH2GG)$D(;2D/ONI2EQYV@^=Q:4`$GJ0!HB M@I(;26F"&EJ:*613\M)36A"!T!JKKHB:S]PKVK.$_<0O.`WOE#*G3[M$4@89"%MAIL(<* ME+0$@)65&JBH4H2H^NB*<(0$!L)2$!(2$`#:$@4``]*`:(J28T="7$)8:2EW M^T2$)`73TW`#K2NB*H&VTK4XE"0M82E:PD!2@BNT*/J0G<:?UZ(@-MAQ3H0D M.+2E"G`D;U(05%"2KU*4E9I_7HBB$)"BL)`4J@4H`5('H"?4TKHBD>89D([; M[3;R#UV.)"T_N((T1'89V):[2.V@@H1M&U)2:B@]!0Z(IBVV5!90DK2*)50; M@.HH#ZCUUY^E&37E%?)*E3;1]@_=H88G;6M/L7VI"E+:#ZH2?ZP#KR^CM:\W MILKY!?0]PV$J`9:!J&T`[M]=HKOZ_-6GKUUZB&(;&C[$YW<3L0&6@L+#:`L! M8"PD!0#B@IP`TK1:D@G[2-5!K1L"^$D[5,4)(VE*2D>@H*"GW:K!(V+X"6_+ MHI.PS3;VF]I^&Q-/W4IK[SNXE5<[^)4GTD7K_=V>O0_EIZ_^FJ7#G;ROU:=Q M7ULCV?*2%.AAE"=B&FTHI3:E(`IUZ4`I3KKS$40C]$-'I<*:?8J7.Q5*IWIZ'[=><=I:PGFBC8UW@`%49)' M"A<2%54VA?XD)5_6D'7J^-D@H\`CQ7P/`HCWND%)"2/%5"A!I5*33TJ!\-5%K7&I%2O@GQ\=ZCKXOJIKI5%=]:]-M?V[J?#1%,K;M5OIM MH=U?3;\:_=3UT16]?:K\GTG9I\=M/7]U::(O8QM[2-G;V]:=JG;_`!'\-.GK M_P"NB*MHB-$1HB-$1HB-$1HB\LG9L7W?P;4[*?VG=JJFSX[O2FB*D>]VF=FS MU'U/>IO[%>NZOQ[?VZ(I87:[CWTO9^DZ;>SMV]W^.FWIZ>OWZ(KCHB-$1HB- M$1HB-$1HB-$1HB-$1HB-$1HB-$1HB-$1HB-$1HB-$1HB-$1HB-$1HB-$7__9 ` end GRAPHIC 4 tlogo2.jpg GRAPHIC begin 644 tlogo2.jpg M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$! M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$" M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,# M`P,#`P,#`P,#_\``$0@`*0`I`P$1``(1`0,1`?_$`)@```,!`0`#```````` M```````("0<$!08*`0`"`P`#````````````````!P,%!@($"!```00!`P($ M!`0'`0```````0(#!`4&`!$'(1(Q010(42(34V$RDA9QT>%2(R05%Q$``0(% M`@,%!@0'`````````0(#`!$Q!`4A!D%A$E%Q@:$RD2(3%!4'L4)2,_#!T6)R M)!;_V@`,`P$``A$#$0`_`/OXT00MF>\_5U/=2,7Q@QYUA!=+%K9N$.1(CA/R(5\O4[[;#%;6>N+<7M[-#2A-*:%0X&?`&,]=YQ"'E6]M( ME-55`/8.?;'D<1Y'FV"FE3I:I'?X]P0D;J^"4)2`/A\-<,Y386,&ECQRV5&.)E:.^3<%6P`=4W%!W! M/GI/_7]OWN5-OD%W#6'G^XVE*E$SJ4JE)'=[W*&`]CLTQ8_%QR6%W\O2X5`= M,N$OS=\A"1H]\GN2XYR:?0YIQOA*)-9-,>SQYV!:TD^&V-MVH\QN7(0Z%H^9 MIY27&U@A74:8ZOMAM#+V:+O'WUPIM:9H6%)6#X:>(T(A=C?FZL;-2W(H,KK64.76(VKC2I\1"CV^K@R&^UJ MTK5+Z!Y`!22`M*21NF]T[.RFUGP+F3MBLR0\GTJY$52KD:\"1#1V_N:QW"R5 M,!3=RGU-J]0YCM',0Q.LG&CC%^9*^-F>%Y;@#SS;*"23K3;<=..R5ME9=09>2LC^U)'5X]))';%+FVDWM@]8@]* MG6E)F:3(T\XE+[!,3E77.=Q"RJ"ZS8\75E@]/KI2%),7)69R*=D.M+`/=&67 M7&R1^9*5:>/W8OD,[7:79*"F+UP24*%N77YZ0J/MW;J>S*T7*9/6J"2DBBY] M)]G"+A?AKS.!(2AXPDOO)X>JLMQF#GL:&TB_QM]B%/D(;2'9]'-=#*6I"P.Y MPP);B5-D[E*5J&^VF7]NMPOV%VYB%J_UGP5)G^1:=3+_`"&AC%[NPC-\P+U( M`N$$`GM3.G.1,(9Q[76O'6;8]F-(I<>936#+KW:2EN56NK#=E"D!)!<8DQ%* M"DG\#X@::&9#67Q;UA<`*;<167YAJE0Y@\8Q./M7<7=HO63[R")R-4\1+LEP MBS'[\H/O.?H_KKSE]/>[4^<.#YH?I,8=RA:NP;*PBN[@H4I2224[MNCZB%C; M<]I!Z$>8UKL*PARU:7X'^/QBDR2_A/*)GU5TYPO^%<@X%@?*-ER/?576 M/)QF\N*/Z1;NHD:5'D5\_(*H]GK;:O0Q]),MI0=<:5LL*(!UJ\MB,ME,&C#V MRT*M6GOB-MK/H)!!"%<$JG/I.@-#&?L+BPL9VZZQS7V]W M8\Y\)%M(]I6D#OG.D7[N[\`RV5EZ>DY!*I]U*QE&,^XUWW(/Y3N1=PW;-%&,:2/>5ZEK)H!1(2` M2H&9I'(SQ@N2\U'1&25R%H82.P;[N$(W\/'8[ZE.<6T/B*4>@<#242HL@XH( M$]3*L-E_Y\U]Y'Z1_+2\^JN?I3&L^47R]LCF%`*TH*CNAP`E!\B#KM8'-_27R'@56BJ@53S`_$<8AR./^<1-LA+P M'@>1_K$Q>2>-.5*.0^S-P;(GTI6I*)=9"=M84C??93$B"'PH$;'8[$?#3MP^ M6-*@1V&%*_P`CL6N5_OV3NW@A"4C<=5`==6F1WOMG",E2GDW% MT*-M'JF10$T2)U)\)Q0VVU,WEW9I:++)5JMP=(`)J$U5I02E.LHK?Q7P3BG$ MF$5>$XXA2V(JU3K6SD)1ZZ]O)"4)F6\]20!WK".QML$I9:`2/`DH3-;HOL[E M',I>_N*T2D>E"11*1RXFJCJ8;^+P=KB<>+"V'N#4J-5*-5*YGR&D:A7X[!@O MIDAM*WF]_I$@;(W&VX&WYP.@/EJD?O'GATE1Z.R+1JW;:U$^J/8-=2)X-$$& ..B"#1!!H@@T00:((__]D_ ` end